Literature DB >> 21045017

Serine phosphorylation of NPM-ALK, which is dependent on the auto-activation of the kinase activation loop, contributes to its oncogenic potential.

Peng Wang1, Fang Wu, Jingdong Zhang, Todd McMullen, Leah C Young, Robert J Ingham, Liang Li, Raymond Lai.   

Abstract

It is well established that the tumorigenic potential of nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK), an oncogenic tyrosine kinase, is dependent on its tyrosine phosphorylation. Using tandem affinity purification-mass spectrometry, we found evidence of phosphorylation of three serine residues of NPM-ALK (Serine¹³⁵, Serine¹⁶⁴ and Serine⁴⁹⁷) ectopically expressed in GP293 cells. Using a specific anti-phosphoserine antibody and immunoprecipitation, we confirmed the presence of serine phosphorylation of NPM-ALK in all three NPM-ALK-expressing cell lines examined. Similar to the tyrosine phosphorylation, phosphorylation of these serine residues was dependent on the activation status of the kinase activation loop of ALK. All of these three serine residues are biologically important as mutation of any one of these residues resulted in a significant reduction in the tumorigenicity of NPM-ALK (assessed by cell viability and clonogenic assay), which correlated with a substantial reduction in the phosphorylation of extracellular signal-regulated kinase 1/2, c-jun N-terminal kinase and signal transducer and activator of transcription 6. Serine phosphorylation of NPM-ALK appears to be regulated by multiple serine kinases since it was markedly reduced by pharmacologic inhibitors for glycogen synthase kinase-3, casein kinase I or mitogen-activated protein kinases. In summary, our study is the first to identify serine phosphorylation of NPM-ALK and to provide evidence that it enhances the tumorigenic potential of this oncogenic protein.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21045017     DOI: 10.1093/carcin/bgq229

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  5 in total

1.  The pathobiology of the oncogenic tyrosine kinase NPM-ALK: a brief update.

Authors:  Raymond Lai; Robert J Ingham
Journal:  Ther Adv Hematol       Date:  2013-04

2.  NPM-ALK mediates phosphorylation of MSH2 at tyrosine 238, creating a functional deficiency in MSH2 and the loss of mismatch repair.

Authors:  K M Bone; P Wang; F Wu; C Wu; L Li; J T Bacani; S E Andrew; R Lai
Journal:  Blood Cancer J       Date:  2015-05-15       Impact factor: 11.037

3.  Phosphoproteomic analysis of anaplastic lymphoma kinase (ALK) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated ALK in neuroblastoma cells.

Authors:  Kamaraj Sattu; Falko Hochgräfe; Jianmin Wu; Ganesh Umapathy; Christina Schönherr; Kristina Ruuth; Damini Chand; Barbara Witek; James Fuchs; Pui-Kai Li; Fredrik Hugosson; Roger J Daly; Ruth H Palmer; Bengt Hallberg
Journal:  FEBS J       Date:  2013-08-22       Impact factor: 5.542

4.  NPM-ALK Is a Key Regulator of the Oncoprotein FOXM1 in ALK-Positive Anaplastic Large Cell Lymphoma.

Authors:  Moinul Haque; Jing Li; Yung-Hsing Huang; Meaad Almowaled; Carter J Barger; Adam R Karpf; Peng Wang; Will Chen; Suzanne D Turner; Raymond Lai
Journal:  Cancers (Basel)       Date:  2019-08-06       Impact factor: 6.639

5.  Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib.

Authors:  Jikui Guan; Susanne Fransson; Joachim Tetteh Siaw; Diana Treis; Jimmy Van den Eynden; Damini Chand; Ganesh Umapathy; Kristina Ruuth; Petter Svenberg; Sandra Wessman; Alia Shamikh; Hans Jacobsson; Lena Gordon; Jakob Stenman; Pär-Johan Svensson; Magnus Hansson; Erik Larsson; Tommy Martinsson; Ruth H Palmer; Per Kogner; Bengt Hallberg
Journal:  Cold Spring Harb Mol Case Stud       Date:  2018-08-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.